{"id":114176,"date":"2024-08-07T10:14:11","date_gmt":"2024-08-07T10:14:11","guid":{"rendered":"https:\/\/www.mymsd.ch\/de\/?page_id=114176"},"modified":"2026-09-30T07:55:12","modified_gmt":"2026-09-30T07:55:12","slug":"keytruda","status":"publish","type":"page","link":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/","title":{"rendered":"KFI Keytruda\u00ae"},"content":{"rendered":"\n<h1 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color mhh-mcn-v1-heading--left mhh-mcn-v1-heading mhh-mcn-v1-heading--c49d335331b5cd11bb2698fadd75d979\"><mark class=\"has-inline-color has-teal-color\">Kurzfachinformation KEYTRUDA\u00ae (Pembrolizumab)<\/mark><\/h1>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--16321a5f44de81c4cf596e878e03bffc wp-block-paragraph\"><strong>KEYTRUDA<sup>\u00ae<\/sup>:<\/strong> <strong>W: <\/strong>Pembrolizumab. I: Erwachsene: Monotherapie indiziert zur Behandlung von nicht resezierbarem oder metastasiertem Melanom und zur adjuvanten Behandlung bei vollst\u00e4ndig reseziertem Melanom Stadium III; Befristete Zulassung: als Monotherapie zur adjuvanten Behandlung mit vollst\u00e4ndig reseziertem Melanom Stadium IIB oder IIC. D: KEYTRUDA\u00ae Infusionsl\u00f6sung ausschliesslich zur i.v. Anwendung verwenden, nicht subkutan, Etikette \u00fcberpr\u00fcfen; i.v. KEYTRUDA\u00ae nicht mit KEYTRUDA\u00ae subkutan ersetzen (andere Dosierung); Umstellung von i.v. KEYTRUDA\u00ae auf KEYTRUDA\u00ae subkutan und umgekehrt m\u00f6glich; Erwachsene: 200 mg i.v. 30 min. 3-w\u00f6chentlich oder 400 mg i.v. 30 min. 6-w\u00f6chentlich; Behandlung bis Krankheitsprogression bzw. Auftreten eines Rezidivs oder bis zu unzumutbarer Toxizit\u00e4t; maximale Behandlungsdauer beim adj. Melanom 12 Mt.<strong><em> Weitere Indikationen und die dazugeh\u00f6rigen Dosierungen f\u00fcr Erwachsene und p\u00e4diatrische Patienten entnehmen Sie bitte der Fachinformation<\/em><\/strong>. <strong>KI<\/strong>: \u00dcberempfindlichkeit gegen\u00fcber Wirk-\/Hilfsstoffen. <strong>WH<\/strong>: Immunvermittelte unerw\u00fcnschte Wirkungen: u.a. Pneumonitis, Kolitis, Hepatitis, Nephritis, Endokrinopathien (einschl. Hypophysitis, Typ-1-Diabetes mellitus, Schilddr\u00fcsenfunktionsst\u00f6rungen; bei TNBC Cortisolspiegel \u00fcberwachen), h\u00e4mophagozytische Lymphohistiozytose (HLH), schwere Hautreaktionen (Stevens-Johnson Syndrom, toxische epidermale Nekrolyse, DRESS Syndrom), andere immunvermittelte unerw\u00fcnschte Wirkungen; immunvermitteltes Myokarditis-Myositis-Myasthenia-gravis-Overlap-Syndrom; Patienten mit vorbestehender Autoimmunerkrankung; Transplantation\/ Stammzelltransplantation (HSZT): Graft-versus-Host-Disease (GvHD) und Lebervenenverschlusskrankheit (VOD); Adjuvante Therapie bei Melanom IIB\/IIC und NSCLC IB\/II\/IIIA: OS Analyse ausstehend; Adjuvante Gabe, nach neoadjuvanter Therapie mit zus\u00e4tzlicher Toxizit\u00e4t verbunden; Einfluss auf nachfolgende Gaben von anti-PD-(L)1-basierten Systemtherapien inkl. Resistenzen bei einem Rezidiv wurde nicht untersucht; Erh\u00f6hte Leberenzyme, wenn KEYTRUDA\u00ae mit Axitinib kombiniert wird (Leberenzyme vor Behandlungsbeginn und w\u00e4hrend der Behandlung \u00fcberwachen); Myokardinfarkt bei Kombination von KEYTRUDA\u00ae mit Lenvatinib bei RCC; Multiples Myelom: erh\u00f6hte Mortalit\u00e4t bei Kombination von KEYTRUDA\u00ae mit Thalidomid-Analogon und Dexamethason; Kombination mit Trastuzumab bei Magenkarzinom siehe Fachinformation von Trastuzumab; Daten zu Immuntherapie Vorbehandlung bei einzelnen Indikationen liegen nicht vor oder solche Patienten wurden von Studien ausgeschlossen; Infusionsbedingte Reaktionen (einschl. \u00dcberempfindlichkeit und Anaphylaxie); Es wurden Patienten von klin. Studien ausgeschlossen (Details siehe Fachinformation); enth\u00e4lt Polysorbat. <strong>DDI:<\/strong> keine bekannt\/ nicht untersucht. <strong>S\/S<\/strong>: nicht empfohlen, Empf\u00e4ngnisverh\u00fctung. <strong>UAW<\/strong> (<strong>sehr h\u00e4ufig<\/strong>): Infektionen der Atemwege, Harnwegsinfektion, An\u00e4mie, Neutropenie, Thrombozytopenie, Hypothyreose, verminderter Appetit, Hypokali\u00e4mie, erniedrigtes Gewicht, Hypomagnesi\u00e4mie, Schlaflosigkeit, Kopfschmerzen, periphere Neuropathie, Dysgeusie, Hypertonie, Blutungen, Dyspnoe, Husten, Dysphonie, Diarrh\u00f6, Abdominalschmerzen, \u00dcbelkeit, Erbrechen, Obstipation, Lipase erh\u00f6ht, orale Entz\u00fcndungen, Stomatitis, erh\u00f6htes ALT und AST, Hautausschlag, makulopapul\u00e4rer Ausschlag, Pruritus, Alopezie, palmar-plantares Erythrodys\u00e4sthesiesyndrom, Schmerzen der Skelettmuskulatur, Arthralgie, Myositis, Schmerzen in den Extremit\u00e4ten, Proteinurie, Kreatinin im Blut erh\u00f6ht, M\u00fcdigkeit\/ Ersch\u00f6pfung, Asthenie, \u00d6deme, Fieber. P: 2 Durchstechflaschen \u00e0 100mg\/ 4ml. <strong>AK<\/strong>: A. Z: MSD Merck Sharp &amp; Dohme AG, B\u00fcrgenstrasse 8, 6005 Luzern, Schweiz. (V31.0). CH-KEY-00084.<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ffc98c54841e8202101bc9207546c1a8 wp-block-paragraph\"><\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\" \/>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--11faba0de6683222457c5da2858e7274 wp-block-paragraph\"><em>Konsultieren Sie bitte vor einer Verschreibung die vollst\u00e4ndige Fachinformation publiziert auf&nbsp;<a href=\"https:\/\/www.swissmedicinfo-pro.ch\/ShowText.aspx?textType=FI&amp;lang=DE&amp;authNr=66231\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo-pro.ch<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kurzfachinformation KEYTRUDA\u00ae (Pembrolizumab) KEYTRUDA\u00ae: W: Pembrolizumab. I: Erwachsene: Monotherapie indiziert zur Behandlung von nicht resezierbarem oder metastasiertem Melanom und zur [&hellip;]<\/p>\n","protected":false},"author":385,"featured_media":0,"parent":114174,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":1711,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[1710],"tags":[1711],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[989],"ga4_page_businessunit":[995],"ga4_page_campaign":[],"ga4_page_content_purpose":[1636],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[1076],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1208],"ga4_page_product":[1502],"ga4_page_region":[1563],"ga4_page_therapeuticarea":[1593],"tx-therapeutic-area":[627],"tx-product":[642],"tx-pathology":[],"tx-content-type":[1712],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-114176","page","type-page","status-publish","hentry","category-kfi","tag-kfi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KFI Keytruda\u00ae - MyMSD.ch DE<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KFI Keytruda\u00ae - MyMSD.ch DE\" \/>\n<meta property=\"og:description\" content=\"Kurzfachinformation KEYTRUDA\u00ae (Pembrolizumab) KEYTRUDA\u00ae: W: Pembrolizumab. I: Erwachsene: Monotherapie indiziert zur Behandlung von nicht resezierbarem oder metastasiertem Melanom und zur [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch DE\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-30T07:55:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2186\" \/>\n\t<meta property=\"og:image:height\" content=\"2134\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytruda\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytruda\\\/\",\"name\":\"KFI Keytruda\u00ae - MyMSD.ch DE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#website\"},\"datePublished\":\"2024-08-07T10:14:11+00:00\",\"dateModified\":\"2026-09-30T07:55:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytruda\\\/#breadcrumb\"},\"inLanguage\":\"de-CH\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytruda\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytruda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Product Succinct Statement\",\"item\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"KFI Keytruda\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/\",\"name\":\"MyMSD.ch DE\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-CH\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-CH\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/wp-content\\\/uploads\\\/sites\\\/13\\\/2026\\\/11\\\/MSD-Logo-square.png\",\"contentUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/wp-content\\\/uploads\\\/sites\\\/13\\\/2026\\\/11\\\/MSD-Logo-square.png\",\"width\":500,\"height\":500,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KFI Keytruda\u00ae - MyMSD.ch DE","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"de_DE","og_type":"article","og_title":"KFI Keytruda\u00ae - MyMSD.ch DE","og_description":"Kurzfachinformation KEYTRUDA\u00ae (Pembrolizumab) KEYTRUDA\u00ae: W: Pembrolizumab. I: Erwachsene: Monotherapie indiziert zur Behandlung von nicht resezierbarem oder metastasiertem Melanom und zur [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/","og_site_name":"MyMSD.ch DE","article_modified_time":"2026-09-30T07:55:12+00:00","og_image":[{"width":2186,"height":2134,"url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/","url":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/","name":"KFI Keytruda\u00ae - MyMSD.ch DE","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/de\/#website"},"datePublished":"2024-08-07T10:14:11+00:00","dateModified":"2026-09-30T07:55:12+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/#breadcrumb"},"inLanguage":"de-CH","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytruda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/de\/"},{"@type":"ListItem","position":2,"name":"Product Succinct Statement","item":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/"},{"@type":"ListItem","position":3,"name":"KFI Keytruda\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/de\/#website","url":"https:\/\/www.mymsd.ch\/de\/","name":"MyMSD.ch DE","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-CH"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/de\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-CH","@id":"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2026\/11\/MSD-Logo-square.png","contentUrl":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2026\/11\/MSD-Logo-square.png","width":500,"height":500,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/114176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/users\/385"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/comments?post=114176"}],"version-history":[{"count":15,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/114176\/revisions"}],"predecessor-version":[{"id":132741,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/114176\/revisions\/132741"}],"up":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/114174"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/media?parent=114176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/categories?post=114176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tags?post=114176"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_audience?post=114176"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_birn_id?post=114176"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_branding?post=114176"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_businessunit?post=114176"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_campaign?post=114176"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=114176"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=114176"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=114176"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_experience?post=114176"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_indication?post=114176"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_material_intent?post=114176"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_product?post=114176"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_region?post=114176"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=114176"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-therapeutic-area?post=114176"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-product?post=114176"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-pathology?post=114176"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-content-type?post=114176"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-active-ingredient?post=114176"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/access?post=114176"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/user_status?post=114176"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/user_role?post=114176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}